Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
INTRODUCTION:
There is a paucity of information regarding markers/factors associated with prostate cancer (PCa) outcome in the United States, especially how these factors differ among racial/ethnic groups. African-American men are more likely to have poorer outcome relative to age and stage-matched Caucasian patients; and very little is known about prognosis and even less about factors that could predict progression among Hispanics. The overall goal of our research project is to identify molecular, epidemiological and clinical markers related to prostate cancer (PCa) progression in a multiethnic cohort of 1,380 PCa patients (773 Caucasians; 361 African Americans, and 246 Mexican Americans).
BODY:

Task 1
Patient Follow-up. (Months 1-30)
a.
Update patient follow-up data by checking clinical schedules and medical charts for updated information. Using a validated medical abstraction form, all patient charts will be abstracted.
b.
Signed medical releases of information will be requested for care received outside of our institution. Copies of medical records will be requested.
c. Death certificates will be obtained for all participants identified as deceased.
d.
Patients' self-reported recurrences (and subsequent treatments) and secondary cancers will be verified.
e. Data will be entered into existing databases. 
In the first year of this grant, we have completed medical record abstractions for 735 prostate cancer patients who have received follow-up care at our institution. Institutional patient records for each participant are being abstracted using the standardized form attached as Appendix A. The most recent clinical follow-up date at our institution is determined; this date is used as the "last date of contact" at the University of Texas MD Anderson Cancer Center (UTMDACC). In addition to baseline treatment information, we abstracted follow-up information
KEY RESEARCH ACCOMPLISHMENTS:
There are no key research accomplishments to report at this time; we are still in the process of collecting follow-up data. No interim analyses have been performed, nor were any planned to be conducted at this time-point.
REPORTABLE OUTCOMES:
Currently, there have been no manuscripts, abstracts, presentations, patents or licenses applied for based on this award. Additionally, there have not been any degrees supported by this award; no cell lines, tissue or serum repositories developed; no informatics nor funding applied for based on work from this award; no employment nor research opportunities applied for and/or received based on experience/training supported by this award.
CONCLUSION:
Our research may help explain ethnic/racial disparities in PCa progression and provide direction towards eliminating these disparities. Additionally, our results may guide future studies to develop ethnic/racial specific interventions (i.e., behavioral, clinical) to improve outcome in the most common cancer in American men.
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APPENDICES:
APPENDIX A:
Medical record abstraction form NOT AVAILABLE -Verify (PATIENT'S NAME) lives at this residence. Ask "Is there a time that I could call back and speak with him?" OR "would you please ask him to call me (INTERVIEWER'S NAME) at (PHONE NUMBER) at his earliest convenience? Thank you for your assistance.
Laboratory results
Post-treatment values
YES -Thank you…(Wait for (PATIENT'S NAME) come to phone) Hello, my name is (INTERVIEWER'S NAME) and I am calling on behalf of MD Anderson Cancer Center, here in Houston. You participated in one of our prostate cancer studies a few years ago, and we are conducting a follow-up study to see how you are doing. Would it be all right with you if I asked you a few questions about your health and updated your information?
• NO -thank you for your time. If you change your mind and would like to participate, please contact me (INTERVIEWER'S NAME) at (PHONE NUMBER).
• YES -I want to let you know that answering these questions is completely voluntary, and you may decide not to answer any or all of them. (Administer risk factor questionnaire (Appendix D))
Following each call, the interviewer logs each call made onto the tracking log for each file, documenting the date, time, phone number dialed, and with whom they spoke. These logs are maintained in the individual patient's study chart, kept in a locked office coded by study identification number. Thank you once again for your time and help with our research project. If we have any more questions in the future, we hope we can call you again.
Test
